Factor Model (net +0.7)
Factor Model
net +0.7 1.7 / 10Piper raises target to $45, keeps Underweight — stabilization, not transformation
Watch: Q1 2026 backfill execution at PharmaCann, 4Front, and Gold Flora, plus life science leasing velocity outside Boston. Material tenant writedowns or delayed backfill would confirm Piper's thesis; clean execution without credit events could pressure the Underweight rating lower.
Piper Sandler raised IIPR's price target by $1 to $45 on February 25, 2026, while maintaining an Underweight rating — a move that perfectly captures the analyst's read: the company's 2025 results are solid, but structural challenges in its cannabis portfolio aren't fixed. IIPR posted $266 million in full-year revenues, $205.4 million in adjusted funds from operations, and $114.4 million in net income, plus declared $7.60 per share in dividends. On the positive side, life science leasing activity in Boston is gaining traction and backfill discussions are active for three troubled cannabis properties (PharmaCann, 4Front, Gold Flora). But legacy tenant credit issues within the cannabis portfolio persist — and Piper sees those as a permanent drag on multiple expansion, not a near-term fix.
The $1 target bump despite north of $200 million in AFFO signals that Piper is pricing IIPR as an income play with ceiling, not a recovery story. Better execution on tenant backfills and life science momentum could narrow the gap between current price and $45, but won't ignite the kind of rerating that would flip the Underweight call. This is a test of management's ability to stabilize without proving they can grow through the cannabis headwind.
Our Trades
Full track record →Long Call · Quick Draw
2026-04-17
Long Call · Quick Draw
2026-04-15
Long Call · Trail Blazer
2026-04-14
Long Call · The Indexer
2026-04-13
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when IIPR changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.